When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CELG - Celgene's Pomalyst nabs accelerated review status in U.S. for Kaposi's sarcoma
Celgene Corporation
The FDA designates Celgene's (NASDAQ:CELG) POMALYST (pomalidomide) a Breakthrough Therapy for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi's sarcoma (KS) who have previously received systemic chemotherapy, as well as patients with HIV?negative KS.
More news on: Celgene Corporation, Healthcare stocks news,